Cytarabine 1000mg/10mL (100mg/mL) Injection

Product Introduction

Cytarabine 1000mg/10mL (100mg/mL) is an antimetabolite chemotherapy used in acute leukaemia, particularly acute myeloid leukaemia. It is a component of induction or consolidation regimens chosen for the type and stage of the blood cancer.

How to use

The oncology team prepares and administers the intravenous treatment on the scheduled treatment days. Standard-dose and high-dose regimens use different infusion schedules and monitoring. Intrathecal treatment requires a separately confirmed preservative-free preparation.

How it works

Cytarabine is converted inside cells to an active nucleotide that inhibits DNA polymerase and DNA formation. It acts most strongly on cells that are making new DNA.

Side effects

Low blood counts, mouth ulcers, nausea, diarrhoea and fever can occur. High-dose treatment may also cause eye inflammation, impaired coordination or other nervous-system toxicity.

Important information

Kidney and liver function influence toxicity risk. Fever, unusual bleeding or new difficulty walking needs prompt assessment. Live vaccines can cause infection during marked immunosuppression.